Article info
PDFResearch ethics
Consent to open label extension studies: some ethical issues
- Correspondence to: Dr P Wainwright, Centre for Philosophy and Healthcare, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK; p.wainwright{at}swansea.ac.uk
Citation
Consent to open label extension studies: some ethical issues
Publication history
- Accepted June 21, 2002
- Revised May 14, 2002
- First published December 1, 2002.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2002 by the Journal of Medical Ethics
Other content recommended for you
- The PATCH trial: efficacy and safety of 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a study protocol for a multicentric, double-blind, enriched enrolment randomised withdrawal, vehicle-controlled study
- Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
- Open label extension studies: research or marketing?
- Long-term safety of pegloticase in chronic gout refractory to conventional treatment
- Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
- Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis
- Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
- When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
- New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel